POTASSIUM-MAGNESIUM CITRATE TRIAL IN PATIENTS COMPLETING LITHOTRIPSY

$0P01FY2000DKNIH

University Of Texas Sw Med Ctr/Dallas, Dallas TX

Investigators

Linked publications & trials

Paper 33582830 Paper 28111301 Paper 27546733 Paper 26679435 Paper 26260319 Paper 25326585 Paper 23553859 Paper 22739230 Paper 22297671 Paper 22247230 Paper 21734082 Paper 21336574 Paper 21170889 Paper 21170871 Paper 21165738 Paper 21124301 Paper 20927039 Paper 20861825 Paper 20703215 Paper 20466874 Paper 20413437 Paper 20096421 Paper 20061383 Paper 19966287 Paper 19846163 Paper 19692486 Paper 19651255 Paper 19360717 Paper 19349416 Paper 19225049 Paper 19157430 Paper 19095203 Paper 19078968 Paper 18853182 Paper 18824592 Paper 18784328 Paper 18710766 Paper 18668025 Paper 18635234 Paper 18606998 Paper 18518781 Paper 18495932 Paper 18448585 Paper 18417539 Paper 18408483 Paper 18407958 Paper 18368028 Paper 18359398 Paper 18359394 Paper 18305097 Paper 18004496 Paper 17882150 Paper 17877442 Paper 17708714 Paper 17702734 Paper 17699358 Paper 17678984 Paper 17671646 Paper 17581925 Paper 17513452 Paper 17478488 Paper 17476495 Paper 17429030 Paper 17334836 Paper 17071327 Paper 17018843 Paper 17014382 Paper 16997051 Paper 16929940 Paper 16775456 Paper 16775450 Paper 16753387 Paper 16736442 Paper 16645424 Paper 16597681 Paper 16443041 Paper 16373673 Paper 16230466 Paper 16221228 Paper 16133066 Paper 16121193 Paper 16046909 Paper 16006907 Paper 15942046 Paper 15931006 Paper 15821508 Paper 15659711 Paper 15599403 Paper 15538246 Paper 15496176 Paper 15388821 Paper 15311008 Paper 15240890 Paper 15213256 Paper 15211456 Paper 15202612 Paper 15086484 Paper 14973148 Paper 14767267 Paper 14717908

Abstract

Description: (Taken directly from the application) The overall goal of this project is to seek a safe alternative to potassium citrate in normocalciuric nephrolithiasis. This goal will be pursued by obtaining validation of the efficacy and safety of K-Mag in an already completed randomized trial, and show that this treatment is particularly effective in normocalciuric patients than in hypercalciuric patients. Thus, a multiclinic, placebo-controlled randomized trail will be conducted with K-Mag. Participating patients will be those with recurrent calcium nephrolithiasis suffering from uncomplicated calcium stone disease who have recently undergone extracorporeal shock Wave Lithotripsy (ESWL) for removal of stones. Both normocalciuric and hypercalciuric patients will be enrolled. The treatment outcome will be analyzed by survival probability (percentage of patients remaining stone-free). The project will test the hypothesis that: 1 K-Mag would be more effective than placebo in inhibiting stone formation in both normocalciuric and hypercalciuric patients, 2 The response of normocalciuric patients K-Mag would be superior to that of hypercalciuric patients, due to the pathogenetic role of hypercalciuria, and 3 The propensity from recurrent stone formation is unaffected by ESWL, thus emphasizing the importance of medical management.

View original record on NIH RePORTER →